Is the efficacy of psychopharmacological drugs comparable to the efficacy of general medicine medication?

BMC Medicine

Volumn 10, Issue , 2012, Pages

  Seemüller, Florian ^a   Möller, Hans Jürgen ^a   Dittmann, Sandra ^a   Musil, Richard ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Effect size; General medicine; Meta analysis; Psychiatry

Indexed keywords

ACETYLSALICYLIC ACID; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HALOPERIDOL; LITHIUM; METFORMIN; PLACEBO; PROTON PUMP INHIBITOR; PSYCHOTROPIC AGENT;

BIPOLAR DISORDER; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DEMENTIA; DIABETES MELLITUS; DRUG EFFICACY; EFFECT SIZE; GENERAL PRACTICE; GLUCOSE BLOOD LEVEL; HUMAN; MANIA; MORTALITY; NOTE; PSYCHOPHARMACOLOGY; REFLUX ESOPHAGITIS; SAMPLE SIZE; SCHIZOPHRENIA; SYSTEMATIC REVIEW; PRESCRIPTION; REVIEW; TREATMENT OUTCOME;

DRUG PRESCRIPTIONS; GENERAL PRACTICE; HUMANS; PSYCHOTROPIC DRUGS; TREATMENT OUTCOME;

EID: 84858753116     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-17     Document Type: Note

References (9)

1. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoSMed 2008, 5:e45.
2. Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009, 339:b2880. 10.1136/bmj.b2880, 2725270, 19671933.
3. Greenberg G. Manufacturing Depression: the Secret History of a Modern Disease 2010, New York, NY: Simon & Schuster.
4. Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012, 200:97-106. 10.1192/bjp.bp.111.096594, 22297588.
5. Moerman DE. Meaningful placebos-controlling the uncontrollable. N Engl J Med 2011, 365:171-172. 10.1056/NEJMe1104010, 21751911.
6. Castaldelli-Maia JM, Scomparini LB, Andrade AG, Bhugra D, de Toledo Ferraz ATC, D'Elia G. Perceptions of and attitudes toward antidepressants: stigma attached to their use-a review. J Nerv Ment Dis 2011, 199:866-871. 10.1097/NMD.0b013e3182388950, 22048139.
7. Benkert O, Kepplinger HM, Sobota K. Psychopharmaka im Widerstreit. Eine Studie zur Akzeptanz von Psychopharmaka und zur Darstellung in den Medien 1995, Berlin/Heidelberg: Springer.
8. Lett HS, Blumenthal JA, Babyak MA, Sherwood A, Strauman T, Robins C, Newman MF. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004, 66:305-315. 10.1097/01.psy.0000126207.43307.c0, 15184688.
9. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993, 270:1819-1825. 10.1001/jama.1993.03510150053029, 8411525.